By Dean Seal
Elanco Animal Health has sold royalty and milestone rights for Xdemvy's human health applications to Blackstone-affiliated funds for $295 million.
The animal-medicine company said Monday that the proceeds from the sale will be used to pay off debt more quickly and lower its leverage ratio.
Elanco previously licensed the antiparasitic agent lotilaner to Tarsus Pharmaceuticals to explore its potential to serve unmet human health needs. In 2023, Xdemvy became the first lotilaner-based product approved for human use and the only federally-approved medicine that treats Demodex blepharitis, a common eyelid disease caused by Demodex mites.
The deal between Elanco and funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance applies certain tiered royalties associated with U.S. net sales of Xdemvy from April of this year through August 2033, as well as certain commercial milestones.
Elanco still has the rights to all royalty payments on net sales outside of the U.S. and future human applications of lotilaner beyond ophthalmic solutions.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
May 05, 2025 07:14 ET (11:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。